Candel Therapeutics, Inc. (CADL) has a MoatMap StockRank of 67/100 based on Quality (34/100), Value (36/100), and Momentum (80/100) factor scores. The current signal is BUY. Candel Therapeutics is a highly speculative, clinical-stage biotech company with low quality metrics and no current revenues, failing our Terry Smith quality filter.
Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing oncolytic viral immunotherapies for the treatment of various cancers. The company leverages a proprietary oncolytic viral platform designed to selectively destroy cancer cells and stimulate systemic anti-tumor immunity. Candel Therapeutics operates as a niche player in the immuno-oncology space, pursuing novel approaches for difficult-to-treat malignancies.
| Price | $8.80 |
| Market Cap | $593M |
| P/E (Forward) | 42.14 |
| Price/Book | 4.92 |
| Return on Equity | -51.2% |
| Return on Invested Capital | -31.0% |
| Debt/Equity | 35.70 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-38M |
Candel Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).